
## Rosario R Le Moli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3065173/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. European Journal of Endocrinology, 2021, 185, G43-G67.	1.9	362
2	Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients. PLoS ONE, 2011, 6, e22552.	1.1	234
3	Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia, 2010, 53, 1743-1753.	2.9	127
4	Determinants of Liver Damage Associated with Intravenous Methylprednisolone Pulse Therapy in Graves' Ophthalmopathy. Thyroid, 2007, 17, 357-362.	2.4	125
5	Determinants of longterm outcome of radioiodine therapy of sporadic non-toxic goitre. Clinical Endocrinology, 1999, 50, 783-789.	1.2	78
6	A simplified diagnostic test for ambulatory screening of peripheral diabetic neuropathy. Diabetes Research and Clinical Practice, 1998, 39, 165-172.	1.1	71
7	A Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma: Clinical and Pathologic Features and Outcomes of 34 Consecutive Cases. Thyroid, 2011, 21, 383-389.	2.4	67
8	A novel methodology for epidemic risk assessment of COVID-19 outbreak. Scientific Reports, 2021, 11, 5304.	1.6	50
9	Insulin Analogs and Cancer. Frontiers in Endocrinology, 2012, 3, 21.	1.5	39
10	Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathy. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 452-457.	1.1	28
11	Graves' Orbitopathy: Extraocular Muscle/Total Orbit Area Ratio is Positively Related to the Clinical Activity Score. European Journal of Ophthalmology, 2012, 22, 301-308.	0.7	27
12	Role of selenium and myo-inositol supplementation on autoimmune thyroiditis progression. Endocrine Journal, 2020, 67, 1093-1098.	0.7	22
13	The tall cell variant of papillary thyroid carcinoma: clinical and pathological features and outcomes. Journal of Endocrinological Investigation, 2013, 36, 249-54.	1.8	22
14	Establishment of reference values for endocrine tests II: Hyperprolactinemia. Netherlands Journal of Medicine, 1999, 55, 71-75.	0.6	21
15	Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients. Diabetes Research and Clinical Practice, 1997, 38, 81-89.	1.1	19
16	Evidence That Baseline Levels of Low-Density Lipoproteins Cholesterol Affect the Clinical Response of Graves' Ophthalmopathy to Parenteral Corticosteroids. Frontiers in Endocrinology, 2020, 11, 609895.	1.5	19
17	Severe Graves' Ophthalmopathy After Percutaneous Ethanol Injection in a Nontoxic Thyroid Nodule. Thyroid, 2012, 22, 210-213.	2.4	18
18	Integrated insulin pump therapy with continuous glucose monitoring for improved adherence: technology update. Patient Preference and Adherence, 2015, 9, 1263.	0.8	15

Rosario R Le Moli

#	Article	IF	CITATIONS
19	Efficacy of Botulinum Toxin <scp>A</scp> for Treating Cramps in Diabetic Neuropathy. Annals of Neurology, 2018, 84, 674-682.	2.8	12
20	Effect of octreotide on insulin requirement, hepatic glucose production, growth hormone, glucagon and c-peptide levels in type 2 diabetic patients with chronic renal failure or normal renal function. Diabetes Research and Clinical Practice, 2001, 51, 45-50.	1.1	11
21	Recent insights into the pathogenesis of autoimmune hypophysitis. Expert Review of Clinical Immunology, 2021, 17, 1175-1185.	1.3	7
22	Effect of octreotide on blood glucose and counterregulatory hormones in insulin-dependent diabetic patients: the role of dose and route of administration. European Journal of Clinical Pharmacology, 1996, 51, 139-144.	0.8	6
23	Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism. Frontiers in Endocrinology, 2020, 11, 367.	1.5	4
24	Onset of Marine-Lenhart syndrome and Graves' ophthalmopathy in a female patient treated with alemtuzumab for multiple sclerosis. Hormones, 2021, 20, 161-165.	0.9	2